Search

Your search keyword '"Schalken, Jack A."' showing total 1,283 results
Start Over Author "Schalken, Jack A."
1,283 results on '"Schalken, Jack A."'

2. Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer

Author

Tolmeijer, Sofie H., van Wilpe, Sandra, Geerlings, Maartje J., von Rhein, Daniel, Smilde, Tineke J., Kloots, Iris S.H., Westdorp, Harm, Coskuntürk, Mustafa, Oving, Irma M., van Ipenburg, Jolique A., van der Heijden, Antoine G., Hofste, Tom, Weiss, Marjan M., Schalken, Jack A., Gerritsen, Winald R., Ligtenberg, Marjolijn J.L., and Mehra, Niven

Published
2024
Full Text
View/download PDF

3. Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting

Author

Mehra, Niven, Kloots, Iris, Vlaming, Michiel, Aluwini, Shafak, Dewulf, Els, Oprea-Lager, Daniela E., van der Poel, Henk, Stoevelaar, Herman, Yakar, Derya, Bangma, Chris H., Bekers, Elise, van den Bergh, Roderick, Bergman, Andries M., van den Berkmortel, Franchette, Boudewijns, Steve, Dinjens, Winand N.M., Fütterer, Jurgen, van der Hulle, Tom, Jenster, Guido, Kroeze, Leonie I., van Kruchten, Michel, van Leenders, Geert, van Leeuwen, Pim J., de Leng, Wendy W.J., van Moorselaar, R. Jeroen A., Noordzij, Walter, Oldenburg, Rogier A., van Oort, Inge M., Oving, Irma, Schalken, Jack A., Schoots, Ivo G., Schuuring, Ed, Smeenk, Robert J., Vanneste, Ben G.L., Vegt, Erik, Vis, André N., de Vries, Kim, Willemse, Peter-Paul M., Wondergem, Maurits, and Ausems, Margreet

Published
2023
Full Text
View/download PDF

6. Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models

Author

van de Merbel, Arjanneke F., van der Horst, Geertje, van der Mark, Maaike H., Bots, Selas T. F., van den Wollenberg, Diana J. M., de Ridder, Corrina M. A., Stuurman, Debra, Aalders, Tilly, Erkens-Schulz, Sigrun, van Montfoort, Nadine, Karthaus, Wouter R., Mehra, Niven, Smits, Minke, Schalken, Jack A., van Weerden, Wytske M., Hoeben, Rob C., and van der Pluijm, Gabri

Published
2022
Full Text
View/download PDF

11. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men

Author

Hendriks, Rianne J., van der Leest, Marloes M. G., Israël, Bas, Hannink, Gerjon, YantiSetiasti, Anglita, Cornel, Erik B., Hulsbergen-van de Kaa, Christina A., Klaver, O. Sjoerd, Sedelaar, J. P. Michiel, Van Criekinge, Wim, de Jong, Hans, Mulders, Peter F. A., Crawford, E. David, Veltman, Jeroen, Schalken, Jack A., Barentsz, Jelle O., and van Oort, Inge M.

Published
2021
Full Text
View/download PDF

12. The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer

Author

Smith, Emma Jane, N'Dow, James, Plass, Karin, Ribal, Maria, Mottet, Nicolas, Shepherd, Robert, Moris, Lisa, Lardas, Michael, Van den Broeck, Thomas, Willemse, Peter-Paul, Campi, Riccardo, Gacci, Mauro, Bjartell, Anders, Evans-Axelsson, LU Susan, Briganti, Alberto, Gandaglia, Giorgio, Crosti, Daniele, Meoni, Massimiliano, Garzonio, Roberto, Bangma, Chris, Roobol, Monique, Remmers, Sebastiaan, Tilki, Derya, Auvinen, Anssi, Murtola, Teemu, Visakorpi, Tapio, Talala, Kirsi, Tammela, Teuvo, Siltari, Aino, Van Hemelrijck, Mieke, Beyer, Katharina, Lejeune, Stephane, van Diggelen, Femke, Byrne, Sophie, Fialho, Luz, Cardone, Antonella, Gono, Paulina, De Meulder, Bertrand, Auffray, Charles, Balaur, Irina-Afrodita, Taibi, Nesrine, Power, Shaun, Kermani, Nazanin Zounemat, van Bochove, Kees, Cirillo, Elisa, Moinat, Maxim, Voss, Emma, Horgan, Denis, Fullwood, Louise, Holtorf, Marc, Lancet, Doron, Bernstein, Gabi, Omar, Imran, MacLennan, Sara, MacLennan, Steven, Tripathee, Sheela, Huber, Johannes, Wirth, Manfred, Froehner, Michael, Brenner, Beate, Borkowetz, Angelika, Thomas, Christian, Horn, Friedemann, Reiche, Kristin, Kreuz, Markus, Josefsson, Andreas, Tandefelt, Delila Gasi, Hugosson, Jonas, Schalken, Jack, Huisman, Henkjan, Hofmarcher, Thomas, Lindgren, Peter, Andersson, Emelie, Fridhammar, Adam, Asiimwe, Alex, Verholen, Frank, Zong, Jihong, Butler-Ransohoff, John-Edward, Williamson, Todd, Chandrawansa, Kumari, Waldeck, Reg, Molnar, Megan, Bruno, Amanda, Herrera, Ronald, Nevedomskaya, Ekaterina, Fatoba, Samuel, Constantinovici, Niculae, Mohamed, Ateesha, Steinbeißer, Carl, Kedhagae, Siddhanth, Maass, Monika, Torremante, Patrizia, Voss, Marc Dietrich, Devecseri, Zsuzsanna, Abbott, Tom, Kiran, Amit, Dau, Chad, Papineni, Kishore, Wang-silvanto, Jing, Hass, Steve, Snijder, Robert, Doyé, Verena, Wang, Xuewei, Garnham, Andy, Lambrecht, Mark, Wolfinger, Russ, Rogiers, Stijn, Servan, Angela, Casariego, Joaquin, Samir, Mohamed, Pascoe, Katie, Robinson, Paul, Reich, Christian, Ratwani, Shilpa, Longden-Chapman, Elaine, Burke, Danny, Agapow, Paul, Derkits, Sahra, Licour, Muriel, Ang, Michelle, Payne, Sarah, Yong, Alan, Thompson, Lucy, Le Mare, Sophia, Bussmann, Michael, Köhler, Inken, Juckeland, Guido, Kotik, Daniel, MacLennan, Sara J., Mastris, Ken, Hooker, Gary, Greene, Robert, Briers, Erik, Omar, Muhammad Imran, Healey, Jemma, Venderbos, Lionne D.F., Smith, Emma J., Bjorkqvist, Josefine, Roobol, Monique J., and N’Dow, James

Published
2021
Full Text
View/download PDF

14. Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.

Author

Slootbeek, Peter H. J., Luna-Velez, María Victoria, Privé, Bastiaan M., van der Doelen, Maarten J., Kloots, Iris S. H., Naga, Samhita Pamidimarri, Onstenk, Hilde E., Nagarajah, James, Westdorp, Harm, van Oort, Inge M., Kroeze, Leonie I., Schalken, Jack. A., Bloemendal, Haiko J., and Mehra, Niven

Published
2024
Full Text
View/download PDF

15. Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?

Author

Slootbeek, Peter H. J., Tolmeijer, Sofie H., Mehra, Niven, and Schalken, Jack A.

Subjects
TISSUE analysis, DNA analysis, CASTRATION-resistant prostate cancer, BIOPSY, TUMOR markers, PATHOLOGICAL laboratories, NUCLEIC acids, DNA repair, DNA damage, TREATMENT effect heterogeneity, EXTRACELLULAR space, GENETIC mutation, COMPARATIVE studies, GENOTYPES, SEQUENCE analysis, ANDROGEN receptors
Abstract

The treatment of metastatic castration-resistant prostate cancer (mCRPC) has been fundamentally transformed by our greater understanding of its complex biological mechanisms and its entrance into the era of precision oncology. A broad aim is to use the extreme heterogeneity of mCRPC by matching already approved or new targeted therapies to the correct tumor genotype. To achieve this, tumor dnA must be obtained, sequenced, and correctly interpreted, with individual aberrations explored for their druggability, taking into account the hierarchy of driving molecular pathways. Although tumor tissue sequencing is the gold standard, tumor tissue can be challenging to obtain, and a biopsy from one metastatic site or primary tumor may not provide an accurate representation of the current genetic underpinning. Sequencing of circulating tumor DNA (ctDNA) might catalyze precision oncology in mCRPC, as it enables real-time observation of genomic changes in tumors and allows for monitoring of treatment response and identification of resistance mechanisms. Moreover, ctDNA can be used to identify mutations that may not be detected in solitary metastatic lesions and can provide a more in-depth understanding of inter- and intra-tumor heterogeneity. Finally, ctDNA abundance can serve as a prognostic biomarker in patients with mCRPC. the androgen receptor (AR)-axis is a well-established therapeutical target for prostate cancer, and through ctDNA sequencing, insights have been obtained in (temporal) resistance mechanisms that develop through castration resistance. new third-generation AR-axis inhibitors are being developed to overcome some of these resistance mechanisms. the druggability of defects in the DNA damage repair machinery has impacted the treatment landscape of mCRPC in recent years. For patients with deleterious gene aberrations in genes linked to homologous recombination, particularly BRCA1 or BRCA2, PARP inhibitors have shown efficacy compared to the standard of care armamentarium, but platinum-based chemotherapy may be equally effective. A hierarchy exists in genes associated with homologous recombination, where, besides the canonical genes in this pathway, not every other gene aberration predicts the same likelihood of response. Moreover, evidence is emerging on cross-resistance between therapies such as PARP inhibitors, platinum-based chemotherapy and even radioligand therapy that target this genotype. Mismatch repair-deficient patients can experience a beneficial response to immune checkpoint inhibitors. Activation of other cellular signaling pathways such as PI3K, cell cycle, and MAPK have shown limited success with monotherapy, but there is potential in co-targeting these pathways with combination therapy, either already witnessed or anticipated. this review outlines precision medicine in mCRPC, zooming in on the role of ctDNA, to identify genomic biomarkers that may be used to tailor molecularly targeted therapies. the most common druggable pathways and outcomes of therapies matched to these pathways are discussed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Exploring the potential of circulating tumour DNA to monitor treatment response in salivary duct carcinoma patients of the CABO-ASAP trial

Author

Weijers, Jetty A.M., primary, de Bitter, Tessa J.J., additional, Verhaegh, Gerald W., additional, van Boxtel, Wim, additional, Uijen, Maike J.M., additional, van Engen-van Grunsven, Adriana C.H., additional, Driessen, Chantal M.L., additional, Schalken, Jack A., additional, Ligtenberg, Marjolijn J.L., additional, and van Herpen, Carla M.L., additional

Published
2023
Full Text
View/download PDF

17. Genomic Predictors of Outcome in Prostate Cancer

Author

Boström, Peter J, Bjartell, Anders S, Catto, James WF, Eggener, Scott E, Lilja, Hans, Loeb, Stacy, Schalken, Jack, Schlomm, Thorsten, and Cooperberg, Matthew R

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Clinical Research, Urologic Diseases, Genetics, Prostate Cancer, Cancer, Human Genome, Prevention, Biotechnology, 4.1 Discovery and preclinical testing of markers and technologies, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, Genomics, Humans, Male, Prognosis, Prostatic Neoplasms, Treatment Outcome, Prostate cancer, Prognostic, Predictive, Outcome, Gene panel, Expression panel, Genetic test, RNA, Cell cycle, DNA, Urology & Nephrology, Clinical sciences
Abstract

ContextGiven the highly variable behavior and clinical course of prostate cancer (PCa) and the multiple available treatment options, a personalized approach to oncologic risk stratification is important. Novel genetic approaches offer additional information to improve clinical decision making.ObjectiveTo review the use of genomic biomarkers in the prognostication of PCa outcome and prediction of therapeutic response.Evidence acquisitionSystematic literature review focused on human clinical studies reporting outcome measures with external validation. The literature search included all Medline, Embase, and Scopus articles from inception through July 2014.Evidence synthesisAn improved understanding of the genetic basis of prostate carcinogenesis has produced an increasing number of potential prognostic and predictive tools, such as transmembrane protease, serine2:v-ets avian erythroblastosis virus E26 oncogene homolog (TMPRSS2:ERG) gene fusion status, loss of the phosphatase and tensin homolog (PTEN) gene, and gene expression signatures utilizing messenger RNA from tumor tissue. Several commercially available gene panels with external validation are now available, although most have yet to be widely used. The most studied commercially available gene panels, Prolaris, Oncotype DX Genomic Prostate Score, and Decipher, may be used to estimate disease outcome in addition to clinical parameters or clinical nomograms. ConfirmMDx is an epigenetic test used to predict the results of repeat prostate biopsy after an initial negative biopsy. Additional future strategies include using genetic information from circulating tumor cells in the peripheral blood to guide treatment decisions at the initial diagnosis and at subsequent decision points.ConclusionsMajor advances have been made in our understanding of PCa biology in recent years. Our field is currently exploring the early stages of a personalized approach to augment traditional clinical decision making using commercially available genomic tools. A more comprehensive appreciation of value, limitations, and cost is important.Patient summaryWe summarized current advances in genomic testing in prostate cancer with a special focus on the estimation of disease outcome. Several commercial tests are currently available, but further understanding is needed to appreciate the potential benefits and limitations of these novel tests.

Published
2015

18. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis

Author

N’Dow, J., Smith, E.J., Shepherd, R., Ribal, M., Mottet, N., Moris, L., Lardas, M., Willemse, P-P., Gandaglia, G., Campi, R., Nicoletti, Rossella, Gacci, M., Briganti, A., Ratti, M.M., Alleva, E., Leardini, L., Sisca, E.S., Bangma, R., Roobol, M., Remmers, S., Tilki, D., Visakorpi, T., Talala, K., Tammela, T., van Hemelrijck, M., Bayer, K., Lejeune, S., Byrne, S., Fialho, L., De Meulder, P. Palaiologou B., Auffray, C., Hijazy, A., Power, S., Kermani, N. Zounemat, van Bochove, K., Kalafati, M., Moinat, M., Voss, E., Horgan, D., Fullwood, L., Holtorf, M., Lancet, D., Bernstein, G., Omar, I., MacLennan, S., Maclennan, S., Tripathee, S., Wirth, M., Froehner, M., Brenner, B., Borkowetz, A., Thomas, C., Horn, F., Reiche, K., Kreux, M., Josefsson, A., Tandefekt, D. Gasi, Hugosson, J., Huisman, H., Schalken, J., Hofmacher, T., Lindgren, P., Andersson, E., Fridhammar, A., Zong, J., Butler-Ransohoff, J-E., Herrera, R., Maass, M., Torremante, P., Voss, M.D., Devecseri, Z., Abbott, T., Dau, C., Papineni, K., Snijder, R., Lambrecht, M., Wolfinger, R., Rogiers, S., Servan, A., Antoni, L., Pacoe, K., Robinson, P., Jaton, B., Bakkard, D., Turunen, H., Kilkku, O., Pohjanjousi, P., Voima, O., Nevalaita, L., Reich, C., Araujo, S., Longden-Chapman, E., Burke, D., Agapow, P., Derkits, S., Licour, M., McCrea, C., Payne, S., Yong, A., Thompson, L., Mare, S. Le, Bussmann, M, Kotik, D., Siltari, Aino, Lönnerbro, Ragnar, Pang, Karl, Shiranov, Kirill, Asiimwe, Alex, Evans-Axelsson, Susan, Franks, Billy, Kiran, Amit, Murtola, Teemu J., Schalken, Jack, Steinbeisser, Carl, Bjartell, Anders, and Auvinen, Anssi

Published
2023
Full Text
View/download PDF

19. Prevention and early detection of prostate cancer

Author

Cuzick, Jack, Thorat, Mangesh A, Andriole, Gerald, Brawley, Otis W, Brown, Powel H, Culig, Zoran, Eeles, Rosalind A, Ford, Leslie G, Hamdy, Freddie C, Holmberg, Lars, Ilic, Dragan, Key, Timothy J, La Vecchia, Carlo, Lilja, Hans, Marberger, Michael, Meyskens, Frank L, Minasian, Lori M, Parker, Chris, Parnes, Howard L, Perner, Sven, Rittenhouse, Harry, Schalken, Jack, Schmid, Hans-Peter, Schmitz-Dräger, Bernd J, Schröder, Fritz H, Stenzl, Arnulf, Tombal, Bertrand, Wilt, Timothy J, and Wolk, Alicja

Subjects
Aging, Prevention, Prostate Cancer, Urologic Diseases, Cancer, Detection, screening and diagnosis, 4.4 Population screening, Age Factors, Aged, Aged, 80 and over, Biomarkers, Tumor, Biopsy, Needle, Early Detection of Cancer, Evidence-Based Medicine, Humans, Immunohistochemistry, Life Style, Male, Middle Aged, Neoplasm Invasiveness, Primary Prevention, Prognosis, Prostate-Specific Antigen, Prostatic Neoplasms, Risk Factors, Risk Reduction Behavior, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer. Early detection of prostate cancer by prostate-specific antigen (PSA) screening is controversial, but changes in the PSA threshold, frequency of screening, and the use of other biomarkers have the potential to minimise the overdiagnosis associated with PSA screening. Several new biomarkers for individuals with raised PSA concentrations or those diagnosed with prostate cancer are likely to identify individuals who can be spared aggressive treatment. Several pharmacological agents such as 5α-reductase inhibitors and aspirin could prevent development of prostate cancer. In this Review, we discuss the present evidence and research questions regarding prevention, early detection of prostate cancer, and management of men either at high risk of prostate cancer or diagnosed with low-grade prostate cancer.

Published
2014

20. TTLL12 has a potential oncogenic activity, suppression of ligation of nitrotyrosine to the C-terminus of detyrosinated α-tubulin, that can be overcome by molecules identified by screening a compound library.

Author

Deshpande, Amit, Brants, Jan, Wasylyk, Christine, van Hooij, Onno, Verhaegh, Gerald W., Maas, Peter, Schalken, Jack A., and Wasylyk, Bohdan

Subjects
CHEMICAL libraries, NITROTYROSINE, MEDICAL screening, TUBULINS, HIGH throughput screening (Drug development), MOLECULES, ENZYME-linked immunosorbent assay
Abstract

Tubulin tyrosine ligase 12 (TTLL12) is a promising target for therapeutic intervention since it has been implicated in tumour progression, the innate immune response to viral infection, ciliogenesis and abnormal cell division. It is the most mysterious of a fourteen-member TTL/TTLL family, since, although it is the topmost conserved in evolution, it does not have predicted enzymatic activities. TTLL12 seems to act as a pseudo-enzyme that modulates various processes indirectly. Given the need to target its functions, we initially set out to identify a property of TTLL12 that could be used to develop a reliable high-throughput screening assay. We discovered that TTLL12 suppresses the cell toxicity of nitrotyrosine (3-nitrotyrosine) and its ligation to the C-terminus of detyrosinated α-tubulin (abbreviated to ligated-nitrotyrosine). Nitrotyrosine is produced by oxidative stress and is associated with cancer progression. Ligation of nitrotyrosine has been postulated to be a check-point induced by excessive cell stress. We found that the cytotoxicities of nitrotyrosine and tubulin poisons are independent of one another, suggesting that drugs that increase nitrotyrosination could be complementary to current tubulin-directed therapeutics. TTLL12 suppression of nitrotyrosination of α-tubulin was used to develop a robust cell-based ELISA assay that detects increased nitrotyrosination in cells that overexpress TTLL12 We adapted it to a high throughput format and used it to screen a 10,000 molecule World Biological Diversity SETTM collection of low-molecular weight molecules. Two molecules were identified that robustly activate nitrotyrosine ligation at 1 μM concentration. This is the pioneer screen for molecules that modulate nitrotyrosination of α-tubulin. The molecules from the screen will be useful for the study of TTLL12, as well as leads for the development of drugs to treat cancer and other pathologies that involve nitrotyrosination. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer

Author

Tolmeijer, Sofie H., primary, van Wilpe, Sandra, additional, Geerlings, Maartje J., additional, von Rhein, Daniel, additional, Smilde, Tineke J., additional, Kloots, Iris S.H., additional, Westdorp, Harm, additional, Coskuntürk, Mustafa, additional, Oving, Irma M., additional, van Ipenburg, Jolique A., additional, van der Heijden, Antoine G., additional, Hofste, Tom, additional, Weiss, Marjan M., additional, Schalken, Jack A., additional, Gerritsen, Winald R., additional, Ligtenberg, Marjolijn J.L., additional, and Mehra, Niven, additional

Published
2023
Full Text
View/download PDF

23. Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Author

Tolmeijer, Sofie H., primary, Boerrigter, Emmy, primary, Sumiyoshi, Takayuki, primary, Kwan, Edmond M., primary, Ng, Sarah W.S., primary, Annala, Matti, primary, Donnellan, Gráinne, primary, Herberts, Cameron, primary, Benoist, Guillemette E., primary, Hamberg, Paul, primary, Somford, Diederik M., primary, van Oort, Inge M., primary, Schalken, Jack A., primary, Mehra, Niven, primary, van Erp, Nielka P., primary, and Wyatt, Alexander W., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure S9 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Author

Tolmeijer, Sofie H., primary, Boerrigter, Emmy, primary, Sumiyoshi, Takayuki, primary, Kwan, Edmond M., primary, Ng, Sarah W.S., primary, Annala, Matti, primary, Donnellan, Gráinne, primary, Herberts, Cameron, primary, Benoist, Guillemette E., primary, Hamberg, Paul, primary, Somford, Diederik M., primary, van Oort, Inge M., primary, Schalken, Jack A., primary, Mehra, Niven, primary, van Erp, Nielka P., primary, and Wyatt, Alexander W., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Methods from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Author

Tolmeijer, Sofie H., primary, Boerrigter, Emmy, primary, Sumiyoshi, Takayuki, primary, Kwan, Edmond M., primary, Ng, Sarah W.S., primary, Annala, Matti, primary, Donnellan, Gráinne, primary, Herberts, Cameron, primary, Benoist, Guillemette E., primary, Hamberg, Paul, primary, Somford, Diederik M., primary, van Oort, Inge M., primary, Schalken, Jack A., primary, Mehra, Niven, primary, van Erp, Nielka P., primary, and Wyatt, Alexander W., primary

Published
2023
Full Text
View/download PDF

26. Data from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Author

Tolmeijer, Sofie H., primary, Boerrigter, Emmy, primary, Sumiyoshi, Takayuki, primary, Kwan, Edmond M., primary, Ng, Sarah W.S., primary, Annala, Matti, primary, Donnellan, Gráinne, primary, Herberts, Cameron, primary, Benoist, Guillemette E., primary, Hamberg, Paul, primary, Somford, Diederik M., primary, van Oort, Inge M., primary, Schalken, Jack A., primary, Mehra, Niven, primary, van Erp, Nielka P., primary, and Wyatt, Alexander W., primary

Published
2023
Full Text
View/download PDF

33. Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?

Author

Smith, Emma, N'Dow, James, Plass, Karin, Ribal, Maria, Mottet, Nicolas, Shepherd, Robert, Abbott, Tom, Mastris, Ken, Moris, Lisa, Lardas, Michael, Van den Broeck, Thomas, Willemse, Peter-Paul, Fossati, Nicola, Pang, Karl, Campi, Riccardo, Greco, Isabella, Gacci, Mauro, Serni, Sergio, Bjartell, Anders, Lonnerbro, Ragnar, Briganti, Alberto, Crosti, Daniele, Garzonio, Roberto, Gandaglia, Giorgio, Faticoni, Martina, Grant office, Bangma, Chris, Jongerden, Maria, Tilki, Derya, Auvinen, Anssi, Murtola, Teemu, Visakorpi, Tapio, Talala, Kirsi, Tammela, Teuvo, Siltari, Aino, Lejeune, Stephane, Colette, Laurence, Caputova, Simona, Poli, Delielena, Byrne, Sophie, Fialho, Luz, Rowland, Ashley, Tapela, Neo, Di Flora, Nicola, Apostolidis, Kathi, Lemair, Valerie, De Meulder, Bertrand, Auffray, Charles, Taibi, Nesrine, Hijazy, Ayman, Saporta, Albert, Sun, Kai, Power, Shaun, Zounemat Kermani, Nazanin, van Bochove, Kees, Tafreshiha, Azadeh, Bernini, Chiara, Horgan, Denis, Fullwood, Louise, Holtorf, Marc, Lancet, Doron, Bernstein, Gabi, Tripathee, Sheela, Wirth, Manfred, Froehner, Michael, Brenner, Beate, Borkowetz, Angelika, Thomas, Christian, Horn, Friedemann, Reiche, Kristin, Kreuz, Markus, Josefsson, Andreas, Gasi Tandefelt, Delila, Hugosson, Jonas, Schalken, Jack, Huisman, Henkjan, Hofmarcher, Thomas, Lindgren, Peter, Andersson, Emelie, Fridhammar, Adam, Tames Grijalva, Monica, Evans-Axelsson, Susan, Verholen, Frank, Zong, Jihong, Butler-Ransohoff, John-Edward, Williamson, Todd, Waldeck, Reg, Bruno, Amanda, Nevedomskaya, Ekaterina, Fatoba, Samuel, Constantinovici, Niculae, Steinbeisser, Carl, Maass, Monika, Torremante, Patrizia, Dochy, Emmanuelle, Pisa, Federica, Voss, Marc Dietrich, Papineni, Kishore, Wang-silvanto, Jing, Snijder, Robert, Wang, Xuewei, Lambrecht, Mark, Wolfinger, Russ, Eid, Sherinne, Palanisamy, Soundarya, Haque, Samiul, Antoni, Laurent, Servan, Angela, Pascoe, Katie, Robinson, Paul, Lencart, Joana, Jaton, Bertrand, Turunen, Heidi, Kilkku, Olavi, Pohjanjousi, Pasi, Voima, Olli, Nevalaita, Liina, Punakivi, Keijo, Seager, Sarah, Ratwani, Shilpa, Grzeslak, Katarzyna, Brash, James, Longden-Chapman, Elaine, Burke, Danny, Licour, Muriel, Payne, Sarah, Yong, Alan, Lujan, Flavia, Le Mare, Sophia, Hendrich, Jan, Bussmann, Michael, Juckeland, Kotik, Reich, Christian, Russell, Beth, Beyer, Katharina, Lawlor, Ailbhe, Roobol, Monique J., Venderbos, Lionne D.F., Remmers, Sebastiaan, Briers, Erik, MacLennan, Sara J., MacLennan, Steven, Omar, Muhammad Imran, and Van Hemelrijck, Mieke

Published
2024
Full Text
View/download PDF

34. Abstract 1802: Personalization of oncolytic virus therapy: Heterogenous anti-tumor responses in preclinical prostate and bladder cancer models

Author

Janssen, Thijs J., primary, van der Horst, Geertje, additional, van der Merbel, Arjanneke F., additional, van der Mark, Maaike, additional, Lamfers, Martine L., additional, Hoogen, Bernadette G. van den, additional, van der Burg, Sjoerd S., additional, Mustafa, Dana A., additional, Mehra, Niven, additional, Aalders, Tilly, additional, van Montfoort, Nadine, additional, Schalken, Jack, additional, Hoeben, Rob C., additional, and van der Pluijm, Gabri, additional

Published
2023
Full Text
View/download PDF

35. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis

Author

Siltari, Aino, primary, Lönnerbro, Ragnar, additional, Pang, Karl, additional, Shiranov, Kirill, additional, Asiimwe, Alex, additional, Evans-Axelsson, Susan, additional, Franks, Billy, additional, Kiran, Amit, additional, Murtola, Teemu J., additional, Schalken, Jack, additional, Steinbeisser, Carl, additional, Bjartell, Anders, additional, Auvinen, Anssi, additional, N’Dow, J., additional, Smith, E.J., additional, Shepherd, R., additional, Ribal, M., additional, Mottet, N., additional, Moris, L., additional, Lardas, M., additional, Willemse, P-P., additional, Gandaglia, G., additional, Campi, R., additional, Nicoletti, Rossella, additional, Gacci, M., additional, Briganti, A., additional, Ratti, M.M., additional, Alleva, E., additional, Leardini, L., additional, Sisca, E.S., additional, Bangma, R., additional, Roobol, M., additional, Remmers, S., additional, Tilki, D., additional, Visakorpi, T., additional, Talala, K., additional, Tammela, T., additional, van Hemelrijck, M., additional, Bayer, K., additional, Lejeune, S., additional, Byrne, S., additional, Fialho, L., additional, De Meulder, P. Palaiologou B., additional, Auffray, C., additional, Hijazy, A., additional, Power, S., additional, Kermani, N. Zounemat, additional, van Bochove, K., additional, Kalafati, M., additional, Moinat, M., additional, Voss, E., additional, Horgan, D., additional, Fullwood, L., additional, Holtorf, M., additional, Lancet, D., additional, Bernstein, G., additional, Omar, I., additional, MacLennan, S., additional, Maclennan, S., additional, Tripathee, S., additional, Wirth, M., additional, Froehner, M., additional, Brenner, B., additional, Borkowetz, A., additional, Thomas, C., additional, Horn, F., additional, Reiche, K., additional, Kreux, M., additional, Josefsson, A., additional, Tandefekt, D. Gasi, additional, Hugosson, J., additional, Huisman, H., additional, Schalken, J., additional, Hofmacher, T., additional, Lindgren, P., additional, Andersson, E., additional, Fridhammar, A., additional, Zong, J., additional, Butler-Ransohoff, J-E., additional, Herrera, R., additional, Maass, M., additional, Torremante, P., additional, Voss, M.D., additional, Devecseri, Z., additional, Abbott, T., additional, Dau, C., additional, Papineni, K., additional, Snijder, R., additional, Lambrecht, M., additional, Wolfinger, R., additional, Rogiers, S., additional, Servan, A., additional, Antoni, L., additional, Pacoe, K., additional, Robinson, P., additional, Jaton, B., additional, Bakkard, D., additional, Turunen, H., additional, Kilkku, O., additional, Pohjanjousi, P., additional, Voima, O., additional, Nevalaita, L., additional, Reich, C., additional, Araujo, S., additional, Longden-Chapman, E., additional, Burke, D., additional, Agapow, P., additional, Derkits, S., additional, Licour, M., additional, McCrea, C., additional, Payne, S., additional, Yong, A., additional, Thompson, L., additional, Mare, S. Le, additional, Bussmann, M, additional, and Kotik, D., additional

Published
2023
Full Text
View/download PDF

40. Supplementary Figure S1 from hTERT-Immortalized Prostate Epithelial and Stromal-Derived Cells: an Authentic In vitro Model for Differentiation and Carcinogenesis

Author

Kogan, Ira, primary, Goldfinger, Naomi, primary, Milyavsky, Michael, primary, Cohen, Merav, primary, Shats, Igor, primary, Dobler, Gabriele, primary, Klocker, Helmut, primary, Wasylyk, Bohdan, primary, Voller, Maureen, primary, Aalders, Tilly, primary, Schalken, Jack A., primary, Oren, Moshe, primary, and Rotter, Varda, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table S1 from TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming

Author

Iljin, Kristiina, primary, Wolf, Maija, primary, Edgren, Henrik, primary, Gupta, Santosh, primary, Kilpinen, Sami, primary, Skotheim, Rolf I., primary, Peltola, Mari, primary, Smit, Frank, primary, Verhaegh, Gerald, primary, Schalken, Jack, primary, Nees, Matthias, primary, and Kallioniemi, Olli, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Materials & Methods from hTERT-Immortalized Prostate Epithelial and Stromal-Derived Cells: an Authentic In vitro Model for Differentiation and Carcinogenesis

Author

Kogan, Ira, primary, Goldfinger, Naomi, primary, Milyavsky, Michael, primary, Cohen, Merav, primary, Shats, Igor, primary, Dobler, Gabriele, primary, Klocker, Helmut, primary, Wasylyk, Bohdan, primary, Voller, Maureen, primary, Aalders, Tilly, primary, Schalken, Jack A., primary, Oren, Moshe, primary, and Rotter, Varda, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure S1 from TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming

Author

Iljin, Kristiina, primary, Wolf, Maija, primary, Edgren, Henrik, primary, Gupta, Santosh, primary, Kilpinen, Sami, primary, Skotheim, Rolf I., primary, Peltola, Mari, primary, Smit, Frank, primary, Verhaegh, Gerald, primary, Schalken, Jack, primary, Nees, Matthias, primary, and Kallioniemi, Olli, primary

Published
2023
Full Text
View/download PDF

44. Data from hTERT-Immortalized Prostate Epithelial and Stromal-Derived Cells: an Authentic In vitro Model for Differentiation and Carcinogenesis

Author

Kogan, Ira, primary, Goldfinger, Naomi, primary, Milyavsky, Michael, primary, Cohen, Merav, primary, Shats, Igor, primary, Dobler, Gabriele, primary, Klocker, Helmut, primary, Wasylyk, Bohdan, primary, Voller, Maureen, primary, Aalders, Tilly, primary, Schalken, Jack A., primary, Oren, Moshe, primary, and Rotter, Varda, primary

Published
2023
Full Text
View/download PDF

45. Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer

Author

Tolmeijer, Sofie H., primary, Boerrigter, Emmy, additional, Sumiyoshi, Takayuki, additional, Kwan, Edmond M., additional, Ng, Sarah, additional, Annala, Matti, additional, Donnellan, Grainne, additional, Herberts, Cameron, additional, Benoist, Guillemette E., additional, Hamberg, Paul, additional, Somford, Diederik M., additional, van Oort, Inge M., additional, Schalken, Jack A., additional, Mehra, Niven, additional, van Erp, Nielka P., additional, and Wyatt, Alexander W., additional

Published
2023
Full Text
View/download PDF

46. Supplementary Table S4-S6 from TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming

Author

Iljin, Kristiina, primary, Wolf, Maija, primary, Edgren, Henrik, primary, Gupta, Santosh, primary, Kilpinen, Sami, primary, Skotheim, Rolf I., primary, Peltola, Mari, primary, Smit, Frank, primary, Verhaegh, Gerald, primary, Schalken, Jack, primary, Nees, Matthias, primary, and Kallioniemi, Olli, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure Legend from hTERT-Immortalized Prostate Epithelial and Stromal-Derived Cells: an Authentic In vitro Model for Differentiation and Carcinogenesis

Author

Kogan, Ira, primary, Goldfinger, Naomi, primary, Milyavsky, Michael, primary, Cohen, Merav, primary, Shats, Igor, primary, Dobler, Gabriele, primary, Klocker, Helmut, primary, Wasylyk, Bohdan, primary, Voller, Maureen, primary, Aalders, Tilly, primary, Schalken, Jack A., primary, Oren, Moshe, primary, and Rotter, Varda, primary

Published
2023
Full Text
View/download PDF

48. Vaccination against Extracellular Vimentin for Treatment of Urothelial Cancer of the Bladder in Client-Owned Dogs

Author

VPDC pathologie, Pathology, Engbersen, Diederik J. M., Beijnum, Judy R. van, Roos, Arno, Beelen, Marit van, Haan, Jan David de, Grinwis, Guy C. M., Schalken, Jack A., Witjes, J. Alfred, Griffioen, Arjan W., Huijbers, Elisabeth J. M., VPDC pathologie, Pathology, Engbersen, Diederik J. M., Beijnum, Judy R. van, Roos, Arno, Beelen, Marit van, Haan, Jan David de, Grinwis, Guy C. M., Schalken, Jack A., Witjes, J. Alfred, Griffioen, Arjan W., and Huijbers, Elisabeth J. M.

Published
2023

49. How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis

Author

Siltari, Aino, Lönnerbro, Ragnar, Pang, Karl, Shiranov, Kirill, Asiimwe, Alex, Evans-Axelsson, Susan, Franks, Billy, Kiran, Amit, Murtola, Teemu J., Schalken, Jack, Steinbeisser, Carl, Bjartell, Anders, Auvinen, Anssi, Roobol, M., Remmers, S., Siltari, Aino, Lönnerbro, Ragnar, Pang, Karl, Shiranov, Kirill, Asiimwe, Alex, Evans-Axelsson, Susan, Franks, Billy, Kiran, Amit, Murtola, Teemu J., Schalken, Jack, Steinbeisser, Carl, Bjartell, Anders, Auvinen, Anssi, Roobol, M., and Remmers, S.

Abstract

Objectives: Genome-wide association studies have revealed over 200 genetic susceptibility loci for prostate cancer (PCa). By combining them, polygenic risk scores (PRS) can be generated to predict risk of PCa. We summarize the published evidence and conduct meta-analyses of PRS as a predictor of PCa risk in Caucasian men. Patients and methods: Data were extracted from 59 studies, with 16 studies including 17 separate analyses used in the main meta-analysis with a total of 20,786 cases and 69,106 controls identified through a systematic search of ten databases. Random effects meta-analysis was used to obtain pooled estimates of area under the receiver-operating characteristic curve (AUC). Meta-regression was used to assess the impact of number of single-nucleotide polymorphisms (SNPs) incorporated in PRS on AUC. Heterogeneity is expressed as I2 scores. Publication bias was evaluated using funnel plots and Egger tests. Results: The ability of PRS to identify men with PCa was modest (pooled AUC 0.63, 95% CI 0.62-0.64) with moderate consistency (I2 64%). Combining PRS with clinical variables increased the pooled AUC to 0.74 (0.68-0.81). Meta-regression showed only negligible increase in AUC for adding incremental SNPs. Despite moderate heterogeneity, publication bias was not evident. Conclusion: Typically, PRS accuracy is comparable to PSA or family history with a pooled AUC value 0.63 indicating mediocre performance for PRS alone.

Published
2023

50. Genetic Aspects and Molecular Testing in Prostate Cancer:A Report from a Dutch Multidisciplinary Consensus Meeting

Author

Mehra, Niven, Kloots, Iris, Vlaming, Michiel, Aluwini, Shafak, Dewulf, Els, Oprea-Lager, Daniela E, van der Poel, Henk, Stoevelaar, Herman, Yakar, Derya, Bangma, Chris H, Bekers, Elise, van den Bergh, Roderick, Bergman, Andries M, van den Berkmortel, Franchette, Boudewijns, Steve, Dinjens, Winand N M, Fütterer, Jurgen, van der Hulle, Tom, Jenster, Guido, Kroeze, Leonie I, van Kruchten, Michel, van Leenders, Geert, van Leeuwen, Pim J, de Leng, Wendy W J, van Moorselaar, R Jeroen A, Noordzij, Walter, Oldenburg, Rogier A, van Oort, Inge M, Oving, Irma, Schalken, Jack A, Schoots, Ivo G, Schuuring, Ed, Smeenk, Robert J, Vanneste, Ben G L, Vegt, Erik, Vis, André N, de Vries, Kim, Willemse, Peter-Paul M, Wondergem, Maurits, Ausems, Margreet, Mehra, Niven, Kloots, Iris, Vlaming, Michiel, Aluwini, Shafak, Dewulf, Els, Oprea-Lager, Daniela E, van der Poel, Henk, Stoevelaar, Herman, Yakar, Derya, Bangma, Chris H, Bekers, Elise, van den Bergh, Roderick, Bergman, Andries M, van den Berkmortel, Franchette, Boudewijns, Steve, Dinjens, Winand N M, Fütterer, Jurgen, van der Hulle, Tom, Jenster, Guido, Kroeze, Leonie I, van Kruchten, Michel, van Leenders, Geert, van Leeuwen, Pim J, de Leng, Wendy W J, van Moorselaar, R Jeroen A, Noordzij, Walter, Oldenburg, Rogier A, van Oort, Inge M, Oving, Irma, Schalken, Jack A, Schoots, Ivo G, Schuuring, Ed, Smeenk, Robert J, Vanneste, Ben G L, Vegt, Erik, Vis, André N, de Vries, Kim, Willemse, Peter-Paul M, Wondergem, Maurits, and Ausems, Margreet

Abstract

BACKGROUND: Germline and tumour genetic testing in prostate cancer (PCa) is becoming more broadly accepted, but testing indications and clinical consequences for carriers in each disease stage are not yet well defined.OBJECTIVE:To determine the consensus of a Dutch multidisciplinary expert panel on the indication and application of germline and tumour genetic testing in PCa.DESIGN SETTING AND PARTICIPANTS: The panel consisted of 39 specialists involved in PCa management. We used a modified Delphi method consisting of two voting rounds and a virtual consensus meeting.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Consensus was reached if ≥75% of the panellists chose the same option. Appropriateness was assessed by the RAND/UCLA appropriateness method.RESULTS AND LIMITATIONS: Of the multiple-choice questions, 44% reached consensus. For men without PCa having a relevant family history (familial PCa/BRCA-related hereditary cancer), follow-up by prostate-specific antigen was considered appropriate. For patients with low-risk localised PCa and a family history of PCa, active surveillance was considered appropriate, except in case of the patient being a BRCA2 germline pathogenic variant carrier. Germline and tumour genetic testing should not be done for nonmetastatic hormone-sensitive PCa in the absence of a relevant family history of cancer. Tumour genetic testing was deemed most appropriate for the identification of actionable variants, with uncertainty for germline testing. For tumour genetic testing in metastatic castration-resistant PCa, consensus was not reached for the timing and panel composition. The principal limitations are as follows: (1) a number of topics discussed lack scientific evidence, and therefore the recommendations are partly opinion based, and (2) there was a small number of experts per discipline.CONCLUSIONS: The outcomes of thi

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results